anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic kidney disease (CKD) is associated with significant reductions in lean body mass and in the mass of various tissues, including skeletal muscle, which causes fatigue and contributes to high mortality rates. In CKD, the cellular protein turnover is imbalanced, with protein degradation outweighing protein synthesis, leading to a loss of protein and cell mass, which impairs tissue function. As CKD itself, skeletal muscle wasting, or sarcopenia, can have various origins and causes, and both CKD and sarcopenia share common risk factors, such as diabetes, obesity, and age. While these pathologies together with reduced physical performance and malnutrition contribute to muscle loss, they cannot explain all features of CKD-associated sarcopenia. Metabolic acidosis, systemic inflammation, insulin resistance and the accumulation of uremic toxins have been identified as additional factors that occur in CKD and that can contribute to sarcopenia. Here, we discuss the elevation of systemic phosphate levels, also called hyperphosphatemia, and the imbalance in the endocrine regulators of phosphate metabolism as another CKD-associated pathology that can directly and indirectly harm skeletal muscle tissue. To identify causes, affected cell types, and the mechanisms of sarcopenia and thereby novel targets for therapeutic interventions, it is important to first characterize the precise pathologic changes on molecular, cellular, and histologic levels, and to do so in CKD patients as well as in animal models of CKD, which we describe here in detail. We also discuss the currently known pathomechanisms and therapeutic approaches of CKD-associated sarcopenia, as well as the effects of hyperphosphatemia and the novel drug targets it could provide to protect skeletal muscle in CKD.
PURPOSE:To obtain a proteinaceous emulsifier low in stimulative property and having strong emulsifying action and moisture holdability, by bonding the amino group part of amino acid ester derived from L-amino acid to the carboxy terminal of hydrophylic protein through an amido linkage. CONSTITUTION:Hydrophylic protein such as casein is reacted with amino acid ester represented by the undermentioned formula in the presence of endopeptitase (e.g., papain) to bond the amino group part of the above mentioned amino acid ester to the carboxy terminal of hydrophilic protein hydrolysate through an amido linkage. R1OR2 (wherein R1 is an amino acid residue and R2 is a saturated hydrocarbon group or an unsaturated hydrocarbon group). Amino acid ester represented by R3CH(NH2)COOR2 (wherein R3 is an alkyl group, an aryl group or an aralkyl group and R2 is same meaning) is pref. from the aspect of high reactivity. Thus obtained proteinaceous emulsifier is low in stimulative property and has strong emulsifying action and moisture holdability.
<P>PROBLEM TO BE SOLVED: To provide a transgenic nonhuman mammal and a transgenic cell capable of expressing a radical fringe transgene comprising a radical fringe coding sequence.  <P>SOLUTION: The transgenic nonhuman mammal and transgenic cell are capable of driving expression of the coding sequence in the mammal by on operably linked regulatory sequence that directs inducible and keratinocyte- specific expression. In the transgenic nonhuman mammal and transgenic cell, the mammal exhibits promoted wound healing and/or increased keratinocyte proliferation following the induction of transgene expression. A polynucleotide sequence (SEQ ID NO: 1) (refer to the specification) and an amino acid sequence (SEQ ID NO: 2) (refer to the specification) for a human radical fringe are provided. A method for treating psoriasis and promoting wound healing comprises administering a modulator of a radical fringe polypeptide activity. A method for identifying the modulator of the radical fringe activity is provided.  <P>COPYRIGHT: (C)2003,JPO
An emergency room triage and intake system management software is provided.  The analysis, encryption, transmission and storage of demographic and critical patient data necessary for both intake and triage assessments is cross-referenced with a pre-existing Emergency Department (ED) dispatch database which may include real-time patient loads, estimated wait-times, hospital capabilities, and distance from the patient. A secondary algorithmic analysis which includes a traffic density and optimal route parameter is included. The outcome of the analysis consists of an optimal ED location, route, and authorization to transmit the totality of the registered patient information to said location. The user is also given the option to authorize the contact of emergency medical services, or to cancel the request. All transmitted and stored data is secured via a cryptosystem. Critical data may be input by any given user, while demographical data may only be modified by the registered user/patient.
BACKGROUND: Spinal cord stimulation is an established technique wherein diverse electrode types are strategically implanted within the spinal epidural space for neuromodulation. Traditional percutaneous puncture cylindrical electrodes (PEs) are predominantly implanted by interventionalists utilizing a percutaneous technique under the monitor of radiation, which is a nonvisualized procedure.
OBJECTIVE: Our study aimed to assess the feasibility of percutaneous endoscope-assisted visualized implantation approach for PEs, delineating its specific merits and demerits compared to the traditional method.
STUDY DESIGN: Laboratory study with Institutional Review Board Number B2023-056SETTING: Clinical Anatomy Research Center, Fudan University.
METHODS: Eight freshly procured adult cadavers (4 women and 4 men) were operated on in this study. They were divided into either Group A or Group B, each encompassing 4 cadavers. Group A was subjected to endoscope-assisted PEs implantation, whereas Group B followed the conventional PEs implantation route.In both groups the operative time of introducer needles placement (OTNP), total operative time (TOT), fluoroscopy time of introducer needles placement (FTNP), and total fluoroscopy time (TFT) were documented and analyzed. Furthermore, the precise positioning of the PEs and any ensuing complications were systematically examined.
RESULTS: Both Group A and Group B successfully executed all predetermined surgical steps. A total of 16 PEs were implanted (dual electrodes in each cadaver): 8 using the percutaneous endoscope-assisted visualized approach (Group A) and 8 via the traditional methodology (Group B). Group A's mean ± SD durations for OTNP, TOT, FTNP, and TFT were 10.25 ± 1.03 minutes, 31.63 ± 5.87 minutes, 4.58 ± 1.35 seconds, and 43.73 ± 14.46 seconds, respectively. In contrast, Group B exhibited mean ± SD times of 11.55 ± 2.81 minutes, 44.75 ± 7.85 minutes, 23.53 ± 4.16 seconds, and 66.30 ± 6.35 seconds for the same metrics. No discernible statistical difference in OTNP and TOT emerged between the groups. However, Group A demonstrated reduced durations for both FTNP and TFT compared to Group B. The optimal position of the PEs was verified via fluoroscopy, with no recorded instances of dura rupture. These outcomes suggest that this endoscope-assisted technique neither increases surgical time nor compromises efficacy. Instead, it leads to a marked reduction in fluoroscopic duration relative to the traditional methodology.
LIMITATIONS: Anatomical study on a human cadaver, the quantity of cadavers, and the procedure's steep learning curve.
CONCLUSION: With the assistance of percutaneous spinal endoscopy, introducer needles can be punctured through the ligamentum flavum at the anticipated interlaminar window locus under direct visualization, improving the convenience of the puncture and reducing fluoroscopic exposure. It is a viable alternative for surgeons from diverse training backgrounds to implant PEs, particularly benefiting those well-versed in endoscopic spine surgery techniques.
Soluble epoxide hydrolase (sEH) inhibition has been shown multiple beneficial effects against brain injuries of Intracerebral hemorrhage (ICH). However, the underlying mechanism of its neuroprotective effects after ICH has not been explained fully. Ferroptosis, a new form of iron-dependent programmed cell death, has been shown to be implicated in the secondary injuries after ICH. In this study, We examined whether sEH inhibition can alleviate brain injuries of ICH through inhibiting ferroptosis. Expression of several markers for ferroptosis was observed in the peri-hematomal brain tissues in mice after ICH. lip-1, a ferroptosis inhibitor, alleviated iron accumulation, lipid peroxidation and the secondary damages post-ICH in mice model. Intraperitoneal injection of 1-Trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl)urea (TPPU), a highly selective sEH inhibitor, could inhibit ferroptosis and alleviate brain damages in ICH mice. Furthermore, RNA-sequencing was applied to explore the potential regulatory mechanism underlying the effects of TPPU in ferroptosis after ICH. C-C chemokine ligand 5 (CCL5) may be the key factor by which TPPU regulated ferroptosis after ICH since CCL5 antagonist could mimic the effects of TPPU and CCL5 reversed the inhibitive effect of TPPU on ferroptosis and the neuroprotective effects of TPPU on secondary damage after ICH. Taken together, these data indicate that ferroptosis is a key pathological feature of ICH and Soluble epoxide hydrolase inhibitor can exert neuroprotective effect by preventing ferroptosis after ICH.
In plants, small-interfering RNAs (siRNAs) mediate epigenetic silencing via the RNA-directed DNA methylation (RdDM) pathway, which is particularly prominent during reproduction and seed development. However, there is limited understanding of the origins and dynamics of reproductive siRNAs acting in different cellular and developmental contexts. Here, we used the RNaseIII-like protein RTL1 to suppress siRNA biogenesis in Arabidopsis pollen, and found distinct siRNA subsets produced during pollen development. We demonstrate that RTL1 expression in the late microspore and vegetative cell strongly impairs epigenetic silencing, and resembles RdDM mutants in their ability to bypass interploidy hybridization barriers in the seed. However, germline-specific RTL1 expression did not impact transgenerational inheritance of triploid seed lethality. These results reveal the existence of multiple siRNA subsets accumulated in mature pollen, and suggest that mobile siRNAs involved in the triploid block are produced in germline precursor cells after meiosis, or in the vegetative cell during pollen mitosis.
The present disclosure relates to maintaining extracted data in a group node profile from electronic activities. A group node profile associated with a group entity is maintained. A first data point including an electronic activity or a record object is accessed. The first data point is parsed using a value detection policy to obtain a first value. The group node profile is updated based on the first value. An association score between the group node profile and the first value is generated. A second data point is accessed. The second data point is parsed. The association score between the group node profile and the first value is updated.
The invention provides a novel compound, which exhibits S1P receptor agonist activity and is excellent as an immunosuppressive agent. In addition, the compound of this invention has few side effects and may be orally administrated. The S1P receptor agonist of the invention includes the compound set forth in the general formula (I), salts thereof, and solvates thereof as active ingredients. In the formula (I), n represents 1, 2, 3, or 4; R.sup.1 represents a hydrogen or C1-C6 alkyl group. R.sup.2 and R.sup.2a each independently represents a hydrogen atom or C1-C6 alkyl group, or R.sup.2 and R.sup.2a may combine together to form a methylene or ethylene group; Ar1 represents a bivalent group derived from naphthalene, 1H-indole, 1H-pyrrolopyridine or benzofuran. Ar.sup.2 represents a phenyl group that can be substituted, a thiophenyl group that can be substituted, or a 1H-pyrazolyl group that can be substituted.
The invention belongs to the technical field of nasal patches and discloses a traditional Chinese medicine nasal patch for tranquilizing and allaying excitement, a preparation method and application thereof. The traditional Chinese medicine volatile oil is composed of anisyl alcohol and valerian oil in parts by weight. The traditional Chinese medicine volatile oil is composed of anisyl alcohol and valerian oil in parts by weight. The nose paste protective layer consists of organic pure cotton cloth and polymer gel. The traditional Chinese medicine nasal paste for tranquilizing and allaying excitement contains the traditional Chinese medicine volatile oil, and can relieve pain, calm and allay excitement. The traditional Chinese medicine nasal paste for tranquilizing and allaying excitement prepared by the invention is pasted in the middle of a human body, can effectively relieve strong anxiety and discomfort, and can be used for tranquilizing and allaying excitement; meanwhile, the traditional Chinese medicine nasal paste for tranquilizing and allaying excitement can be carried about and applied at any time, the application scene is not limited, and the effect is good.
Plasma levels of SIRT-1, IL-6, FGF-23, sclerostin, calcium, phosphate, PTH and urine excretion of total protein, albumin, creatinine, calcium and phosphate are measured at baseline. Then the patients receive three intravenous daily pulses of methylprednisolone of 500 mg followed by oral prednisone 0.8-1.0 mg/kg/24h. The same measurements are repeated 4, 7 and 30 days after starting the steroid treatment.
Care Partners and Persons with Dementia. Up to 40 Care Partners and their 40 care-recipients with ADRD will participate in this study. The primary focus of this study is on Care Partners, however, we will gather subjective and objective data on participants with Alzheimer's Disease and Related Dementias (ADRD) to assess the effect of the intervention on Care Partner affective responses to caregiving and quality of life for both. STELLA participants will be recruited from the existing cohort of patients, and their Care Partners, who are enrolled in the Oregon Roybal Center for CAre Support Translational Research Advantaged by Integrating Technology) ORCASTRAIT Life Laboratory (OSLL).
The primary objective of the study is to evaluate the safety and tolerability of MTP-131 in healthy volunteers following a single intravenous infusion. The secondary objective is to evaluate the pharmacokinetics of MTP-131. This is a double-blind, placebo-controlled, randomized trial. A total of 40 eligible subjects will be enrolled and randomized in a 3:1 active to placebo ratio for a total of 5 treatment groups of 8 volunteers. As far as is logistically possible, each treatment group will have similar numbers of male and female volunteers. After the last subject for each cohort has completed the day 3 clinical assessment and no stopping rules have been met according to Safety Review Board decision, the next cohort will commence.
Neuroimmune communication in the body forms a bridge between two central regulatory systems of the body, i.e., nervous and immune systems. The cholinergic system is a crucial modulatory neurotransmitter in the central and peripheral nervous system. It includes the neurotransmitter acetylcholine (ACh), the enzyme required for the synthesis of ACh (choline acetyltransferase, ChAT), the enzyme required for its degradation (acetylcholinesterase, AChE), and cholinergic receptors (Nicotinic acetylcholine receptors and muscarinic acetylcholine receptors). The cholinergic system in neurons is well known for its role in cognitive function, sensory perception, motor control, learning, and memory processes. It has been shown that the non-neuronal cholinergic system (NNCS) is present in various tissues and immune cells and forms a neuroimmune communications system. In the present review, we discussed the NNCS on immune cells, its role in homeostasis and inflammatory reactions in the gut, and how it can be exploited in treating inflammatory responses.
A combined pharmaceutical preparation has two sequential administration hormonal components that are separately packed in a packaging unit. Each hormonal component consists of a plurality of separately packed daily dosage units that may be individually withdrawn from the package. A first hormonal component contains as hormonal active substance a combination of an oestrogen preparation and of a gestagen preparation in a dose that is at least sufficient to inhibit ovulation. The second hormonal component contains as hormonal active substance only an oestrogen preparation. The first hormonal component comprises 23 or 24 daily units and the second hormonal component comprises 4, 3, or 2 daily units. Between both hormonal components are placed 2 or 1 active substance-free daily units (placebos) or are indicated 2 or 1 pill-free days. The total number of hormonal daily units and active substance-free daily units or pill-free days equals the total number of days in the desired cycle that has however at least 28 days. This combined preparation for feminine contraception has an as low as possible oestrogen content in each individual dosing unit and also a low total hormone content per administration cycle, while having a high contraceptive safety, a low incidence of follicle development, and allowing an irreproachable cycle control and reliably avoiding spotting and undesirable side effects.
Amines (I), which prevent formation of nitrosamines on reacting with NOx, or contain accepting groups for nitrosing agents, in which on further reaction produce no or very small amts. of carcinogenic nitrosamines, are used in body care preparations, cutting fluids and hydraulic oils as described in the patent application DE3818495. The novelty is that the amines can be trishydroxymethyl-aminomethane, aromatic (di)amines, aromatic aminophenols and aromatic methylsubd. amines opt. substd. with carboxylic acids or sulphonic acids, or their (alkali)ne earth and ammonium salts. They can also be aid amides of aliphatic or aromatic carboxylic and sulphonic acid substd. (di)amines, amino phenols, methyl substd. aryl amines or their (alkali)ne earth and ammonium amido sulphamate salts. ADVANTAGE - (I) neutralise the acidic components in the materials mentioned, thus inhibiting formation of nitrosamine.
PURPOSE: A pharmaceutical composition containing luteolin as an active ingredient for preventing and treating hyperosmia is provided to suppress recognition of disgusting smell from various olfactory stimulants by suppressing or reducing cyclic AMP (cAMP) generation, thereby effectively preventing and treating hyperosmia. CONSTITUTION: A pharmaceutical composition for preventing and treating hyperosmia contains luteolin as an active ingredient. Luteolin reduces cAMP concentration. The pharmaceutical composition is manufactured in a formulation selected from a group consisted of an oral formulation, an external use formulation, a suppository, a sterilized injection solution, and a spray. A health functional food for preventing and alleviating hyperosmia contains luteolin as an active ingredient. An aroma composition contains luteolin as an active ingredient.
A group of 45 individuals with the clinical findings of oculocutaneous albinism (OCA) will be randomly assigned to one of 3 treatment groups: treatment with 0.76 mg/kg/d with 25% carbidopa, 0.51 mg/kg/d levodopa with 25% carbidopa \[divided into 3 doses/d), or placebo. Subjects will be between ages 3 and 60 years. Blood will be drawn to determine the mutation(s) in the genes that causes OCA. Primary outcome will be binocular best-corrected visual acuity measured with the EVA. Enrollment and 20 week examination will be complete eye exam with fundus photos. At weeks 5, 10, and 15, exams will include just vital signs and BCVA. At all visits, a review of potential side effects will be conducted. Between visits, subjects will be contacted to determine if any side effects have occurred. The study will remain double masked until the last study examination on the last subject has been performed. At that time, the data will be statistically analyzed and subjects will be informed re: treatment assignment, mutations found, and the study results.
This study will aim to verify the effect of home versus supervised exercise programs in migraine patients. The primary outcomes will be changes in the Visual Analog Scale (VAS) (0-10) and Migraine Disability Assessment Scores (MIDAS). Secondary outcomes will be changes in cervical range of motion; change in muscle endurance test; neck disability index (NDI), Headache Impact Test (HIT-6) score, Patient Health Questionnaire (PHQ-9) scores, Generalized Anxiety Disorder (GAD-7) scores.

Volunteers for the study will be included if they are between 18 and 55 years old, are of either sex, have been diagnosed with migraine according to the third edition of the International Classification of Headache, and have exhibited at least 3 days with migraine attacks in the previous month, then will be randomly assigned into two groups. A single therapist will administer the interventions twice a week for 8 weeks. The experimental group (supervised) will carry out a supervised exercises program twice a week in comparison with the control group (no supervised) and will carry out a home-based exercise program twice a week. These volunteers will be recruited at the University of Gran Rosario, (Rosario, Argentina). Primary and secondary outcomes will be measured at both groups' baseline and the end of the treatment. All the evaluations will be performed by a blinded physiotherapist
A large body of evidence suggests that depression is associated with a increased risk of many chronic diseases, including hypertension, diabetes, stroke and particularly coronary heart disease. Post stroke depression (PSD) may develop as a result of vascular disease. A previous meta-analysis showed that depression significantly increased the risk of development of stroke, and this increase was probably independent of other risk factors, including hypertension and diabetes.

Clarifying this issue has important implications; if depression increases the risk of development of recurrent stroke, so treating PSD might decrease the occurrence of recurrent stroke. To our knowledge there is no study attempting to clarify the relationship between PSD treatment and stroke recurrence. To fill these gap, we systematically conducted a study to assess whether PSD is associated with recurrent stroke, cardiovascular events or death. Thus, in the current study, three different arms of follow-up of patients with first-ever stroke, were used to predict the outcome over 52 weeks.
The aim of the study was to evaluate the radiographic evidence of periapical healing in teeth with apical periodontitis treated in a single visit with an additional final irrigation using 2% chlorhexidine and to compare the results with conventional multiple-visit root canal treatment (RCT) with an intracanal calcium hydroxide dressing as a control group. 100 asymptomatic molar teeth with periapical lesions were treated using engine-driven nickel-titanium (NiTi) instrumentation with 2.5% sodium hypochlorite (NaOCl) and 5% ethylenediaminetetraacetic acid (EDTA) as irrigants. Half of the teeth were randomly assigned to the one-visit (OV) group and received an additional final rinse with 2% chlorhexidine (CHX) before obturation. The other teeth were treated in two visits (TV), after completion of root canal instrumentation calcium hydroxide paste was placed into the root canal and root canal obturation was performed in second visit. All patients were recalled and investigated clinically and radiographically for 48 months. Changes in apical bone density indicating radiographic healing were evaluated.
The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV \>16%, restore the head height to 45°, and 250ml carbonated Ringer's solution was infused (infusion time \>10min).